Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,083 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Residual ANTXR1+ myofibroblasts after chemotherapy inhibit anti-tumor immunity via YAP1 signaling pathway.
Licaj M, Mhaidly R, Kieffer Y, Croizer H, Bonneau C, Meng A, Djerroudi L, Mujangi-Ebeka K, Hocine HR, Bourachot B, Magagna I, Leclere R, Guyonnet L, Bohec M, Guérin C, Baulande S, Kamal M, Le Tourneau C, Lecuru F, Becette V, Rouzier R, Vincent-Salomon A, Gentric G, Mechta-Grigoriou F. Licaj M, et al. Among authors: kamal m. Nat Commun. 2024 Feb 12;15(1):1312. doi: 10.1038/s41467-024-45595-3. Nat Commun. 2024. PMID: 38346978 Free PMC article.
The spectrum of clinical trials aiming at personalizing medicine.
Le Tourneau C, Kamal M, Alt M, Verlingue L, Servois V, Sablin MP, Servant N, Paoletti X. Le Tourneau C, et al. Among authors: kamal m. Chin Clin Oncol. 2014 Jun;3(2):13. doi: 10.3978/j.issn.2304-3865.2014.05.02. Chin Clin Oncol. 2014. PMID: 25841410 Free article.
Design and statistical principles of the SHIVA trial.
Paoletti X, Asselain B, Kamal M, Servant N, Huppé P, Bieche I, Le Tourneau C. Paoletti X, et al. Among authors: kamal m. Chin Clin Oncol. 2015 Sep;4(3):32. doi: 10.3978/j.issn.2304-3865.2015.02.02. Chin Clin Oncol. 2015. PMID: 26408299 Free article. Review.
Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials.
Le Tourneau C, Kamal M, Tsimberidou AM, Bedard P, Pierron G, Callens C, Rouleau E, Vincent-Salomon A, Servant N, Alt M, Rouzier R, Paoletti X, Delattre O, Bièche I. Le Tourneau C, et al. Among authors: kamal m. J Natl Cancer Inst. 2015 Nov 23;108(4):djv362. doi: 10.1093/jnci/djv362. Print 2016 Apr. J Natl Cancer Inst. 2015. PMID: 26598514 Free PMC article. Review.
The SHIVA01 trial: what have we learned?
Le Tourneau C, Kamal M, Bièche I. Le Tourneau C, et al. Among authors: kamal m. Pharmacogenomics. 2017 Jun;18(9):831-834. doi: 10.2217/pgs-2017-0062. Epub 2017 Jun 8. Pharmacogenomics. 2017. PMID: 28594293 No abstract available.
Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie.
Basse C, Morel C, Alt M, Sablin MP, Franck C, Pierron G, Callens C, Melaabi S, Masliah-Planchon J, Bataillon G, Gardrat S, Lavigne M, Bonsang B, Vaflard P, Pons Tostivint E, Dubot C, Loirat D, Marous M, Geiss R, Clément N, Schleiermacher G, Kamoun C, Girard E, Ardin M, Benoist C, Bernard V, Mariani O, Rouzier R, Tresca P, Servois V, Vincent-Salomon A, Bieche I, Le Tourneau C, Kamal M. Basse C, et al. Among authors: kamal m. ESMO Open. 2018 Apr 6;3(3):e000339. doi: 10.1136/esmoopen-2018-000339. eCollection 2018. ESMO Open. 2018. PMID: 29636991 Free PMC article.
Molecular profiling in precision medicine oncology.
Le Tourneau C, Borcoman E, Kamal M. Le Tourneau C, et al. Among authors: kamal m. Nat Med. 2019 May;25(5):711-712. doi: 10.1038/s41591-019-0442-2. Nat Med. 2019. PMID: 31036881 No abstract available.
2,083 results